Ironwood Pharmaceuticals Inc (IRWD)
6.48
-0.01
(-0.15%)
USD |
NASDAQ |
Jul 08, 10:18
Ironwood Pharmaceuticals Research and Development Expense (TTM): 129.05M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 129.05M |
| December 31, 2023 | 116.08M |
| September 30, 2023 | 90.86M |
| June 30, 2023 | 69.42M |
| March 31, 2023 | 46.29M |
| December 31, 2022 | 44.26M |
| September 30, 2022 | 65.67M |
| June 30, 2022 | 65.03M |
| March 31, 2022 | 65.74M |
| December 31, 2021 | 70.40M |
| September 30, 2021 | 54.82M |
| June 30, 2021 | 65.61M |
| March 31, 2021 | 75.52M |
| December 31, 2020 | 88.06M |
| September 30, 2020 | 98.33M |
| June 30, 2020 | 104.19M |
| March 31, 2020 | 110.87M |
| December 31, 2019 | 115.04M |
| September 30, 2019 | 116.75M |
| June 30, 2019 | 118.35M |
| March 31, 2019 | 112.78M |
| December 31, 2018 | 117.09M |
| September 30, 2018 | 68.88M |
| June 30, 2018 | 76.79M |
| March 31, 2018 | 90.95M |
| Date | Value |
|---|---|
| December 31, 2017 | 88.14M |
| September 30, 2017 | 146.55M |
| June 30, 2017 | 147.01M |
| March 31, 2017 | 141.35M |
| December 31, 2016 | 139.49M |
| September 30, 2016 | 128.68M |
| June 30, 2016 | 116.98M |
| March 31, 2016 | 113.95M |
| December 31, 2015 | 108.75M |
| September 30, 2015 | 108.60M |
| June 30, 2015 | 107.89M |
| March 31, 2015 | 101.39M |
| December 31, 2014 | 101.89M |
| September 30, 2014 | 96.92M |
| June 30, 2014 | 94.82M |
| March 31, 2014 | 96.77M |
| December 31, 2013 | 102.38M |
| September 30, 2013 | 108.14M |
| June 30, 2013 | 108.57M |
| March 31, 2013 | 116.72M |
| December 31, 2012 | 113.47M |
| September 30, 2012 | 109.42M |
| June 30, 2012 | 108.88M |
| March 31, 2012 | 96.05M |
| December 31, 2011 | 86.09M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
44.26M
Minimum
Dec 2022
129.05M
Maximum
Mar 2024
83.79M
Average
75.52M
Median
Mar 2021
Research and Development Expense (TTM) Benchmarks
| Amicus Therapeutics Inc | 139.21M |
| Insmed Inc | 564.23M |
| Altimmune Inc | 70.04M |
| Cassava Sciences Inc | 83.54M |
| InfuSystems Holdings Inc | -- |